Ocular Therapeutix (OCUL) Misses Q4 EPS by 7c

Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.52), $0.07 worse than the analyst estimate of ($0.45).

• PDUFA Target Action Date of July 19, 2017 for the DEXTENZA™ NDA for the Treatment of Ocular Pain Occurring After Ophthalmic Surgery

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Ocular Therapeutix (OCUL) PT Raised to $25 at H.C. Wainwright
• C.H. Robinson acquires DeSpir Logistics for $75 million
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings